Pemetrexed: all 524 studies that test it
Page 6 of 6. Open to participants first (73), then studies with results posted, then the rest; newest registration first within each.
- Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal CancerCompletedNCT00079872Phase 2
- A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung CancerCompletedNCT00078260Phase 3
- Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast CancerCompletedNCT00072865Phase 2
- Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00071136Phase 1/2
- Pemetrexed Disodium in Treating Young Patients With Recurrent Solid TumorsCompletedNCT00070473Phase 1
- Pemetrexed as First Line Chemotherapy for Advanced Breast CancerCompletedNCT00065533Phase 2
- Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal MesotheliomaCompletedNCT00061477Phase 2
- Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.CompletedNCT00061464Phase 2
- Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical TrialCompletedNCT00061451Phase 2
- Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder CancerCompletedNCT00059865Phase 1/2
- Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal CancerTerminatedNCT00055432Phase 2
- Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the UrotheliumCompletedNCT00053209Phase 2
- ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.CompletedNCT00051506Phase 2
- ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.CompletedNCT00051493Phase 2
- A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the UrotheliumCompletedNCT00035061Phase 2
- A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.CompletedNCT00035035Phase 3
- A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.CompletedNCT00034619Phase 2
- Comparing 3 Schedules of Alimta Plus GemzarCompletedNCT00034606Phase 2
- A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00034593Phase 2
- A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.CompletedNCT00034502Phase 1/2
- ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic CancerCompletedNCT00034463Phase 1
- Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT00022646Phase 2
- Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by SurgeryCompletedNCT00005636Phase 3
- LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney FunctionCompletedNCT00003706Phase 1